About
Imricor is a medical device company founded in 2006, specializing in MRI-compatible products for cardiac catheter ablation procedures. It is the first company globally to offer commercially viable MRI-guided cardiac ablation products, enhancing the safety and effectiveness of ablation therapy for patients. The company is headquartered in the United States and is publicly listed on the Australian Securities Exchange since 2019. Imricor's key innovations include the Vision-MR Ablation Catheter, Vision-MR Dispersive Electrode, and Vision-MR Diagnostic Catheter, all designed for use under real-time MRI guidance. This technology provides superior imaging quality, leading to better patient outcomes and reduced radiation exposure. Imricor focuses on the cardiac ablation market, which addresses conditions affecting over 80 million patients worldwide. The company is actively expanding its presence in Europe and preparing for a pivotal FDA trial in the United States, aiming to broaden its market reach.
Technologies
Keywords
Company Information
-
Employees 75
-
Founded 2006
-
Annual Revenue $959000
-
Total Funding $3070178
Location
400 Gateway Blvd, Burnsville, Minnesota, United States, 55337